

OFFICIAL RECORD COPY

MATERIALS LICENSE

Amendment No. 12

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letters listed in Condition 15	
1. Metropolitan Hospital, Inc.		3. License Number	45-17395-01
		is amended in its entirety to read as follows:	
2. 701 West Grace Street Richmond, Virginia 23220		4. Expiration Date	March 31, 2003 (Extended)
		5. Docket or Reference No.	030-12684
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300 (iodine 131 in capsule form only)	C. As needed (Not to exceed 10 curies of I-131)	
D. Any byproduct material identified in 10 CFR 31.11	D. Prepackaged Kits	D. As needed	

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.
- D. In vitro studies.

CONDITIONS

- 10. Location for use: Metropolitan Hospital, 701 West Grace Street, Richmond, Virginia 23220
- 11. Radiation Safety Officer: Maurice F. Mullins, M.D.

010063
9611040251 961010
PDR ADOCK 03012684
C PDR

2/1
ML 20

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-17395-01Docket or Reference Number
050-12684

Amendment No. 12

continued

CONDITIONS

12. Authorized user(s):

- A. Maurice F. Mullins, M.D. for materials identified in 10 CFR 33.100, 35.200, 35.300 and 31.11.
- B. James J. Zelenak M.D. for materials identified in 10 CFR 35.100, 35.200, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction.
- C. Henry Bernard Showalter, Jr., M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- D. Gerald Yount, Jr., M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- E. George W. Martin, M.D. for materials identified in 10 CFR 35.100, 35.200, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction.
- F. Efsthathois Spinos, M.D. for materials identified in 10 CFR 35.100, 35.200, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.
- G. Glen L. Shivel, M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- H. Joel Parker, M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- I. Scott Cunningham, M.D. for materials identified in 10 CFR 35.100 and 31.11.
- J. Timothy R. Taylor, M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- K. Ray A. Beauchamp, M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- L. R. West Fuller, M.D. for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- M. W. Powell Baker, M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- N. Patricia K. Buchanan, M.D. for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- O. Jeffrey Jones, M.D. for materials identified in 10 CFR 35.100 35.200, 35.300 and 31.11.
- P. Keith Thompson, M.D. for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- Q. Jeffrey Hull, M.D. for materials identified in 10 CFR 35.100, 35.200 and 31.11.

13. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

14. The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facilities listed in Condition 10 pursuant to the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number 45-17395-01

Docket or Reference Number 050-12684

Amendment No. 12

continued


CONDITIONS

15. Except as specifically provided otherwise in the license and as provided in 10 CFR 35.51, the licensee shall conduct its program in accordance with statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter with attachments dated September 23, 1992

B. Letters dated:

- March 4, 1993 (with attachments)
- March 23, 1993
- December 12, 1994 (change of ownership)
- June 15, 1995 (add and delete users)
- October 16, 1995 (add users)
- March 1, 1996 (NRC letter extends expiration date in accordance with 10 CFR 30.36)
- July 29, 1996 (add user)



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

Date OCT 10 1996

J. M. / 96

By *Earl G. Wright*

Region II, Division of Nuclear Materials Safety
101 Marietta Street, Suite 2900
Atlanta, GA 30323

OCT 15 1996

Metropolitan Hospital
ATTN: Maurice F. Mullins, M.D.
Radiation Safety Officer
701 West Grace Street
Richmond, Virginia 23220

Dear Dr. Mullins:

SUBJECT: TRANSMITTAL AND EXPLANATION OF MATERIALS LICENSE
(REFERENCE CONTROL NO. 257228; DOCKET NO. 030-12684)

Enclosed is Amendment No. 12 to License No. 45-17395-01 issued in response to your notification letters dated June 15, 1995, October 16, 1995 and July 29, 1996. This amendment has been issued in order to avoid any confusion in the future in regard to users on your license and an amendment fee will not be required. Your license renewal date has also been extended for five years in accordance with 10 CFR 30.36. Revisions to your license are printed in **BOLD** typeface. Please review this document carefully and be sure that you understand all of its provisions.

If you have questions about this letter or your license, please call Mr. Earl G. Wright at (404) 331-5617.

Sincerely,

Earl G. Wright
Senior License Reviewer
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 12

SEND	OFC	RII:DRSS	RII:DRSS	RII:DRSS		
TO	NAME	EWright <i>EW</i>	CHosey			
PDR	DATE	10/ 11 /96	10/ /96	/ /	/ /94	/ /94
Yes	No	COPY?	Yes	No	Yes	No

OFFICIAL RECORD COPY

DOCUMENT NAME: G:\DRSS\257228.egw

August 19, 1996

Metropolitan Hospital
ATTN: Maurice F. Mullins, M.D.
Radiation Safety Officer
701 West Grace Street
Richmond, VA 23220

SUBJECT: ACKNOWLEDGEMENT OF NOTIFICATION OF SELECTION OF
AUTHORIZED USERS UNDER 10 CFR 35.14

Gentlemen:


We have received your subject notification dated July 29, 1996 but will not amend your license at the present time. We will add (or delete) the Authorized Users designated in your letter during the next amendment or renewal of your license. You should retain copies of your Radiation Safety Committee records on this matter for review during our next inspection.

As an amendment fee is not required at this time, our License Fees Branch will return your check after processing.

We appreciate your cooperation in this matter. If you have questions, please call me at (404) 331-4673. Our fax numbers are (404) 331-7437/4449. A copy of this letter and your letter will be placed in the Public Document Room in accordance with 10 CFR 2.790.

Sincerely,

Diane M. Heim
Licensing Assistant
Division of Nuclear Materials Safety

SEND TO PUBLIC DOCUMENT ROOM?		YES		NO	
OFFICE	RII:DRSS	RII:DRSS			
SIGNATURE					
NAME	CMHossey				
DATE	08 / 20 / 96	08 / / 96	08 / / 96	08 / / 96	08 / / 96
COPY?	YES NO	YES NO	YES NO	YES NO	YES NO

OFFICIAL RECORD COPY DOCUMENT NAME: G:\DRSS\NMLS\LICLTR\met.1tr

Metropolitan Hospital+

701 West Grace Street • Richmond, Virginia 23220
(804) 775-4100

July 29, 1996

Nuclear Materials Safety Section
US Nuclear Regulatory Commission Region II
Suite 2900
101 Mariette St. NW
Atlanta, GA 30303

Dear Sir:


Metropolitan Hospital is requesting the addition of one authorized user to the radioactive material license of Metropolitan Hospital #45-17395-01. The Radiation Safety Committee met on May 28, 1996 and reviewed the qualifications of one individual to be added to the radioactive material license as authorized user.


Dr. Patricia K. Buchanan was unanimously approved for diagnostic use of by-product material identified in 10 CFR 35.100, 35.200, 35.300 and 31.11 based on board certification by American Board of Radiology and Documented training and experience criteria. Copies of certification from the American Board of Radiology are included.

An amendment fee of \$440.00 has been enclosed.

If you have any questions please contact Maurice Mullins, M.D. at (804) 775-4195 or James J. Zelenak, M.D. at (804) 320-3911.

Sincerely,


Patrick Gray, CEO


Maurice F. Mullins, M.D., RSO

Enclosures

257162

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Charles Teates MD

2. STATE OR TERRITORY IN
WHICH LICENSED TO
PRACTICE MEDICINE

VA

3. CERTIFICATION

SPECIALTY BOARD
A

CATEGORY
B

MONTH AND YEAR CERTIFIED
C

Radiology

Diplomate

June 1994

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	July 1, 1990 - June 30, 1994 University of VA Charlottesville, VA 22908	100	50
b. RADIATION PROTECTION	"see above"	30	20
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	see above	20	5
d. RADIATION BIOLOGY	see above	20	
e. RADIOPHARMACEUTICAL CHEMISTRY		30	10

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Tc-99m	30 mCi	University of Virginia Hospital, Charlottesville VA. 22908 ↓	1040 hours Total ↓	Clinical ↓ 207162
Mb-99	3000 mCi			
I-131	200 mCi			
Yb 181	500 uCi			
In 111	5 mCi			
Ga 67	10 mCi			
Tl-201	4 mCi			
I 125	50 uCi			

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Patricia K. Buchanan, MD

STREET ADDRESS

2470 Marekintown Ferry Road

CITY

Middleton, VA

STATE

VA

ZIP CODE

23113

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	76	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	3	
	LIVER FUNCTION STUDIES	1	
	FAT ABSORPTION STUDIES	0	
	KIDNEY FUNCTION STUDIES	0	
	IN VITRO STUDIES	1	
OTHER			
I-125	DETECTION OF THROMBOSIS	2	
I-131	THYROID IMAGING	5	
P-32	EYE TUMOR LOCALIZATION	0	
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY	7	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	152	
OTHER			
Tc-99m	BRAIN IMAGING	20	
	CARDIAC IMAGING	378	
	THYROID IMAGING	3	
	SALIVARY GLAND IMAGING	1	
	BLOOD POOL IMAGING	3	
	PLACENTA LOCALIZATION	0	
	LIVER AND SPLEEN IMAGING	39	
	LUNG IMAGING	167	
	BONE IMAGING	486	
OTHER	Tc-99m Renal	128	

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	0	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	0	
I-131	TREATMENT OF THYROID CARCINOMA	6	
	TREATMENT OF HYPERTHYROIDISM	30	
Au-198	INTRACAVITARY TREATMENT	0	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	0	
	INTRACAVITARY TREATMENT	0	
I-125 or Ir-192	INTERSTITIAL TREATMENT	0	
Co-60 or Cs-137	TELETHERAPY TREATMENT	0	
Sr-90	TREATMENT OF EYE DISEASE	0	
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	50	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	45	
Other			
Ga-67	Gallium Scan	37	
In-111	OncoScint Scan	2	
Tc-99m	WBC Scan	14	
Tc-99m	Parathyroid Scan	4	
I-131	MITB	3	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

July 1, 1990 - June 30, 1994 University of VA Hospital
Charlottesville VA 22908
1040 hours experience

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Charles D. Teates, MD

b. NAME OF INSTITUTION

University of Virginia Hospital

c. MAILING ADDRESS

Box 486 UVA Medical Center

d. CITY

Charlottesville, VA 22908

5. MATERIALS LICENSE NUMBER(S)

45-00034-26

6. PRECEPTOR'S SIGNATURE

Charles D. Teates

7. PRECEPTOR'S NAME (Please type or print)

CHARLES D. TEATES

8. DATE

3/8/96

207102

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radiology Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and the American Association of Physicians in Medicine
Society and for the

Patricia Kay Buchanan

Has pursued an arduous course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of

The American Board of Radiology

On this ninth day of June, 1994

Hasby demonstrating to the satisfaction of the Board
that she is qualified to practice the specialty of
Diagnostic Radiology

For Rogers MD Sec 9 Plm N Del Cpt. N.D.



207102

October 26, 1995

Metropolitan Hospital
ATTN: Patrick A. Romano
Corporate Executive Officer
701 West Grace Street
Richmond, Virginia 23220

SUBJECT: ACKNOWLEDGEMENT OF NOTIFICATION OF SELECTION OF AUTHORIZED USERS
UNDER 10 CFR 35.14

Gentlemen:

We have received your subject notification dated October 16, 1995 but will not amend your license at the present time. We will add (or delete) the Authorized Users designated in your letter during the next amendment or renewal of your license. You should retain copies of your Radiation Safety Committee records on this matter for review during our next inspection.


We appreciate your cooperation in this matter. If you have questions, please call me at (404) 331-4673. Our fax numbers are (404) 331-7437/4449. A copy of this letter and your letter will be placed in the Public Document Room in accordance with 10 CFR 2.790.

Sincerely,



Diane M. Heim
Licensing Assistant
Division of Nuclear Materials Safety

45-17395-01

SEND TO PUBLIC DOCUMENT ROOM?		YES	NO
OFFICE	RII:DRSS		
SIGNATURE			
NAME	CMHisey		
DATE	10 / 26 / 95	10 / / 95	10 / / 95
COPY?	YES NO	YES NO	YES NO

OFFICIAL RECORD COPY


DOCUMENT NAME: G:\DRSS\NMLS\LICLTR\mhva.1tr

SEND TO PUBLIC DOCUMENT ROOM?		YES	NO				
OFFICE	RH:DRSS	RH:DRSS					
SIGNATURE	<i>CMH</i>						
NAME	CMHosey						
DATE	10 / 24 / 95	10 / / 95	10 / / 95	10 / / 95	10 / / 95	10 / / 95	10 / / 95
COPY?	YES <u>NO</u>	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO

OFFICIAL RECORD COPY

DOCUMENT NAME: G:\DRSS\NMLS\LICLTR\mhva.1tr

• notation -
add next revision
for 35,100, 200 &
300



Metropolitan Hospital+

701 West Grace Street • Richmond, Virginia 23220
(804) 775-4100

October 16, 1995

Nuclear Materials Safety Section
US Nuclear Regulatory Commission Region II
Suite 2900
101 Mariette St. NW
Atlanta, GA 30303

Dear Sir:


Metropolitan Hospital is requesting the addition of two authorized users to the radioactive material license of Metropolitan Hospital #45-17395-01. The Radiation Safety Committee met 8-30-95 and reviewed the qualifications of two individuals to be added to the radioactive material license as authorized users.

Drs. Jeffrey Jones and Keith Thompson were unanimously approved for diagnostic use of by-product material identified in 10 CFR 35.300, at the August 30th Radiation Safety Committee meeting, based on the fact that they were added to Retreat Hospital NRC license.


Please change all mailings to Maurice F. Mullins, M.D., R.S.O.

If you have any questions please contact Maurice Mullins, M.D. at (804) 775-4195 or James J. Zelenak, M.D. at (804) 254-5400.

Sincerely,



Patrick A. Romano, CEO



Maurice F. Mullins, M.D., RSO

256773

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

45-15048-01

Docket or Reference Number

030-08485

Amendment No. 33

(continued)

CONDITIONS

12. Authorized users:

- A. James J. Zelenak, M.D., for materials identified in 10 CFR 35.100, 35.200, 31.11, and iodine 131 as sodium iodide for the treatment of hyperthyroidism and cardiac dysfunction.
- B. Maurice F. Mullins, M.D. for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- C. **Jeffrey E. Jones, M.D., for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.**
- D. Henry Bernard Showalter, Jr., M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- E. B. Gerald Yount, Jr., M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- F. George W. Martin, M.D., for materials identified in 10 CFR 35.100, 35.200, 31.11, and iodine 131 as sodium iodide for the treatment of hyperthyroidism and cardiac dysfunction.
- G. Efsthios Spinos, M.D., for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- H. Glen L. Shivel, M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- I. Joel F. Parker, M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- J. Scott Cunningham, M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- K. Timothy R. Taylor, M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- L. Ray A. Beauchamp, M.D., for materials identified in 10 CFR 35.100, 35.200, and 31.11.
- M. R. West Fuller, M.D., for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- N. W. Powell Baker, M.D., for materials identified in 10 CFR 35.100, 35.200 and 31.11.
- O. **J. Keith Thompson, M.D., for materials identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.**
- P. **Jeffrey E. Hull, M.D., for materials identified in 10 CFR 35.100, 35.200 and 31.11.**

- 13. Sealed sources containing licensed material shall not be opened by the licensee.
- 14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.
- 15. The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facilities listed in Condition 10 per the provision of 10 CFR 30.35(g) until this license is terminated by the Commission.

256773